Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. New eye prosthetic for corneal blindness could help meet global demand

New eye prosthetic for corneal blindness could help meet global demand

Stories May 3, 2022 3 minutes

The fully synthetic cornea is less likely to be rejected, making it a much-needed alternative that requires no donor tissue.

In the first study of its kind, a global team of researchers are investigating the safety and effectiveness of the CorNeat KPro synthetic cornea in people with corneal blindness. The fully artificial cornea could be a game-changer for patients with corneal blindness, replacing the need for human donations and providing a much-needed alternative for patients who did not respond to current technology. 

Vancouver Coastal Health Research Institute researcher Dr. Alfonso Iovieno is the lead of the British Columbia arm of the study, and brings to the table years of experience in research and clinical care to improve treatments for corneal disease.

“When a person who has been blind for a decade or more regains their sight, you witness a transformation in their whole persona,” says Iovieno. 

“It is like they come back to life. They regain their enthusiasm. They can read again. They can talk to more people again. It is life-changing.”

The fourth most common cause of vision loss across the world, corneal blindness happens when disease or trauma renders the outer transparent layer of the eye opaque. Around 500 British Columbians are waiting for cornea replacement surgery at any given time, some anywhere from six months to one year. 

Globally, corneal opacity — or varying degrees of corneal blindness — affects around 4.2 million people, according to the World Health Organization. Yet, a 2016 study found that over half of the global population had no access to replacement surgery; and, for every one cornea available, 70 were needed.

Dr. Alfonso Iovieno is a clinical associate professor in the Department of Ophthalmology and Visual Sciences at the University of British Columbia.

CorNeat corneas integrate more completely into the eye

Restoring the sight of a person with corneal blindness requires either a human donor cornea or a plastic polymer prosthetic cornea, aka, keratoprosthesis. Current keratoprosthesis often involves a skirt of human donor tissue around the edges of the synthetic cornea to secure it to the patient’s eye. 

“While a fully human donor cornea could encounter graft rejection, standard keratoprosthesis with a human cornea component carries the risk of degradation and infection of the biologic part,” says Iovieno. 

Cornea replacements can last between 10 to 20 years or more. However, the more replacement surgeries a person has, the greater the likelihood of a rejection, Iovieno explains. As global populations age, the demand for corneal replacements will likely continue to grow.

“In general, patients who have had three or more corneal transplants will have around a 100 per cent chance of rejecting another corneal transplant.”

The CorNeat KPro is a different type of keratoprosthesis. The entirely artificial cornea uses an electrospun nanofibre skirt to attach to the sclera, or the white of the eye, in a complex surgical procedure that takes around one hour to complete.

Similar to other artificial corneas, the centre of the prosthesis has a transparent polymer optical membrane that the patient can see through to replace their damaged, non-transparent cornea.

The fact that the CorNeat cornea is fully synthetic reduces the chances of it not integrating with the patient’s eye, says Iovieno. In contrast to other corneal prostheses, the CorNeat KPro gradually integrates with the eye’s fibroblast and collagen connective tissue cells.

“The white of the eye can grow into the spongy material of the CorNeat prosthesis, similar to a synthetic bone mesh,” he explains. “That is where the attachment happens, as opposed to at the edges of the cornea with donor tissue.”

Watch a news report of the first patient to receive a CorNeat KPro cornea:

While researchers are still investigating its safety and long-term effectiveness, Iovieno says there is a great deal of optimism that the CorNeat KPro could provide a valuable alternative for many patients at risk of rejecting donor tissues. Its 100 per cent manufactured materials could also help meet the high-demand for corneal replacements worldwide. 

“If, in the future, CorNeat is seen as a safe substitute to a human cornea, it could cut down on wait times for this sight-saving treatment.” 

Visit the clinical trial page to learn more about participating in Iovieno’s study.

 

Researchers

Alfonso Iovieno

Related Articles

Behind the lab doors: Eye Care Centre

Novel AI model explains retinal sex difference

Transformative treatment for wet, age-related macular degeneration

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Other Research Focus Areas

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy